Arimidex (anastrozole) is a medication that is commonly used to treat breast cancer, particularly in postmenopausal women. In the United States, it is approved to treat hormone receptor-positive breast cancer in postmenopausal women. Arimidex, anastrozole, and its generic form, Arimidex (anastrozole) are among the most commonly prescribed drugs in the United States.
In addition to its use for treating breast cancer, Arimidex has also been prescribed off-label to manage symptoms such as fatigue, joint pain, and hot flashes associated with menopause. Its use is also being evaluated by the Food and Drug Administration (FDA) for potential interactions with certain other medications and supplements.
While Arimidex is not approved to be used off-label for the treatment of breast cancer, doctors may recommend the use of Arimidex for patients with a history of breast cancer. This review will look at how Arimidex, anastrozole, and its generic form, Arimidex (anastrozole), compare to other drugs that may be prescribed off-label for breast cancer.
Anastrozole, the generic form of Arimidex, is a selective estrogen receptor modulator (SERM). It works by inhibiting estrogen receptor activity, which may be one of the ways in which Arimidex helps reduce the risk of developing estrogen-related breast cancer. Arimidex (anastrozole) is FDA approved to treat hormone receptor-positive breast cancer in postmenopausal women. Arimidex is not FDA approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women.
The dosage of Arimidex depends on the individual patient's condition. Dosages can be based on several factors, including the patient's age, the hormone level, and the duration of their breast cancer treatment.
The Arimidex dosage for postmenopausal women is typically prescribed at a lower level than that for Arimidex. However, the Arimidex dosage for postmenopausal women may be adjusted to a higher or lower level depending on how the patient responds to the medication.
For Arimidex to be effective, the dosage of Arimidex for a particular patient is typically determined by the following factors:
It is important to note that Arimidex may not be completely safe for women taking certain medications, such as anti-androgens or hormonal birth control methods. In some cases, Arimidex may not be appropriate for a patient with a history of breast cancer.
Arimidex, the generic form of Arimidex, works by blocking estrogen receptors in the breast tissue, which can reduce the risk of estrogen-related breast cancer. Arimidex is FDA approved to treat hormone receptor-positive breast cancer in postmenopausal women.
Introduction
Women who have taken Aromatase inhibitors, such as Arimidex, Anastrozole, and Femara, have been reported to have an increased risk of cancer. The purpose of this study was to investigate the risk of breast cancer in women who take Arimidex, Anastrozole, or Femara, and to evaluate the effects of taking these drugs on the risk of cancer.
In a population-based study, women who took Aromatase inhibitors or Arimidex, an aromatase inhibitor, had a higher risk of breast cancer compared to women who took the other two drugs. The findings were analyzed for women who were currently taking Aromatase inhibitors, an aromatase inhibitor, and were treated with Aromatase inhibitors or Arimidex, an aromatase inhibitor, for one year.
Methods
This was a population-based case-control study (n = 9,942) with a population of patients who have taken Arimidex, an aromatase inhibitor, and were treated with Arimidex or an aromatase inhibitor, an aromatase inhibitor, for one year. Controls were a matched group of women who have had breast cancer for one year. In the case group, women who were treated with Arimidex or an aromatase inhibitor were excluded from the study. The same analysis was performed for controls who had never taken Arimidex or an aromatase inhibitor.
We used the following data for the analysis: age, BMI, and duration of treatment with Arimidex, an aromatase inhibitor, and duration of treatment with Arimidex or an aromatase inhibitor. All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA). The median duration of treatment with Arimidex, an aromatase inhibitor, and duration of Arimidex or an aromatase inhibitor were the 95th and 95th percentiles of the absolute range for the median duration of treatment with Arimidex, an aromatase inhibitor, and duration of Arimidex or an aromatase inhibitor, respectively.
Product name:Arimidex®
Company name:
DIN:02991715
Status:Marketed
Status date:2020-12-31
| Active ingredient(s) | Strength |
|---|---|
| Arimidex | 1 mg |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
The administration of the drug Arimidex (anastrozole) to a male patient who is receiving hormone therapy has been reported to reduce the risk of breast cancer recurrence.1,2,3 The most common side effect reported with oral Arimidex administration is hot flashes.3 In patients receiving anastrozole therapy, hot flashes are observed in about 25% of patients.4,5 In anastrozole-induced hot flashes, patients receiving anastrozole therapy may report fatigue, insomnia, headache, dry mouth, and a decrease in blood pressure, which may be accompanied by depression.5,6
Patients with hepatic cirrhosis, patients with liver metastases, and patients with the following conditions should avoid using Anastrozole. Patients with thromboembolic disorders, including myelopathy, should avoid Anastrozole.1,2
The most common adverse effects reported with the use of Anastrozole during the first month of therapy include: headache, abdominal pain, nausea, fatigue, abdominal pain, abdominal cramps, diarrhea, and dyspepsia.1-4 Patients receiving Anastrozole-induced hot flashes during the first month of therapy should also avoid Anastrozole, since Aromatase Inhibitors may increase the risk of hot flashes.5 Patients who experience breast cancer recurrence, and patients who have undergone chemotherapy or radiotherapy, should avoid Anastrozole.1,2
The most common adverse effects reported with the use of Anastrozole during the first month of therapy are: headache, nausea, vomiting, constipation, diarrhea, dry mouth, constipation, dry mouth, constipation, dizziness, somnolence, abdominal pain, and headache.1-4 Patients who experience hot flashes during Anastrozole therapy should avoid Anastrozole, since Anastrozole may increase the risk of hot flashes.1,2
Some potential interactions are listed in theList of Interactionssection.1-4 Patients with liver dysfunction, severe hepatic insufficiency, and a history of an increased risk of blood clots, may also experience an increased risk of anastrozole-induced hot flashes.1,2
Some medicines may interact with Anastrozole. Patients with hypersensitivity to anastrozole or any of its ingredients should avoid Anastrozole.1,2
The use of Anastrozole during pregnancy is not recommended by the FDA. Anastrozole may cause abnormalities of the fetus.1,2
The safety and effectiveness of Anastrozole in pregnancy have not been established.1,2
The Arimidex 1 mg tablet contains an active ingredient called Anastrozole. It is used to treat breast cancer in women who have not responded to hormone therapy. Arimidex 1 mg tablets are also used to treat an enlarged prostate (benign prostatic hyperplasia - BPH). BPH is a common condition where a woman's prostate gland is enlarged. This can prevent blood from causing the smooth muscle surrounding the prostate gland (proliferating muscle).
The Arimidex 1 mg tablet should not be taken with medicines or alcohol. It is also not recommended to take Arimidex 1 mg tablet if you are allergic to it, or if you are pregnant or are trying to get pregnant. Let others know of any side effects it has had on you.
The Arimidex 1 mg tablet is usually taken orally, with or without food, as directed by your doctor. The dosage and duration of treatment will vary depending on the individual. A dose of 1 mg/day will usually be prescribed for as long as the doctor has been examining you. Treatment with 1 mg/day or more of Arimidex 1 mg tablet usually last for a few days to a week. The amount of time you will be taking Arimidex 1 mg tablet will vary depending on the individual. It is usually recommended to take Arimidex 1 mg tablet for as long as recommended by your doctor. Some medicines may interact with Arimidex 1 mg tablet including other breast cancer medication, alcohol, blood thinners, and HIV/AIDS medicines.
Read More About Arimidex 1 mg Tablet and Other MedicinesRead more about:+ stories, newsletters, tips and more.While Arimidex 1 mg tablet is generally safe for use, it may cause side effects in some people. Side effects can include hot flashes, mood changes, visual disturbances (blurred or dimmered), nausea, stomach pain or discomfort, and sweating. If you experience any of these side effects, stop taking Arimidex 1 mg tablet and contact your doctor right away.
Some side effects can be more bothersome than others. These are:
• Dry mouth • Nasal congestion • Congested or runny nose • Yellowing of the skin or eyes (jaundice) • Flushing (warmth, redness, or tinge to the skin) • Headache • Dizziness or dizziness • Muscle pain or spasms (myalgia) • Muscle weakness (spasms, cramps) or cramps • Shortness of breath (difficulty breathing) or trouble swallowing • Stomach discomfort or upset (nausea, vomiting, stomach cramps) and stomach cramps.
If you experience any of these symptoms while taking Arimidex 1 mg tablet, stop taking it and contact your doctor right away.
In the US:
• Onset of action: Early treatment of breast cancer can help slow growth of cancer cells in the body. Treatment usually takes around five to six months for most patients. Some medicines may interact with Arimidex 1 mg tablet including Arimidex 1 mg Tablet, other breast cancer medicine, alcohol, blood thinners, HIV/AIDS medicines, and medicines for anxiety.
In Canada:
• Inform your doctor if you are taking any other prescribed or nonprescribed medicines, herbal supplements, or vitamins, as this may affect how Arimidex 1 mg tablet is administered.
ReferencesFenoff, D. (2021). "Anastrozole and the Norwood's Syndrome." Clinical Pharmacology (Basel), 73:1-14.
Curtis, B. M. "The Arimidex 1 mg Tablet." Clinical Pharmacology (Basel), 73:1-14.
(1949). "The Arimidex 1 mg Tablet." Drug (Basel), 19:21-28.
(1960). "The Arimidex 1 mg Tablet." Clinical Pharmacology (Basel), 35:1195-98.
(1958). "The Arimidex 1 mg Tablet." Clinical Pharmacology (Basel), 35:1195-99.
Rosenblatt, D. R. et al.
Stade de France Pharmacy